GlaxoSmithKline reviews remuneration

Drugs giant GlaxoSmithKline today said it was still reviewing its remuneration policy including controversial two-year rolling contracts awarded to executives which sparked a shareholder protest.

Earlier today, French-born chief executive Dr Garnier was reported to be ready to give up part of the £22m (€32m) “golden parachute” package he would have received if he lost his job.